SCHEMBL6724604

SCHEMBL6724604

CC(C#N)(O[Si](C)(C)C)c1ccc2ccccc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 2/20 0.37
PTPN1 P18031 2/20 0.35
CYP3A4 P08684 3/20 0.35
CYP2D6 P10635 3/20 0.35
SLC6A2 P23975 3/20 0.35
SLC6A4 P31645 3/20 0.35
SLC6A3 Q01959 3/20 0.35
KCNH2 Q12809 3/20 0.35
CYP1A2 P05177 2/20 0.34
CYP2A6 P11509 2/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20176066 0.87 CYP2D6 (0.34) CASRPTPN1CYP3A4CYP2D6SLC6A2
SCHEMBL6563216 0.85 KIF11 (0.32)
SCHEMBL1269231 0.83 MAPK1 (0.39) CYP3A4CYP2D6ALDH1A1RAB9AKMT2A
SCHEMBL3709877 0.77 APP (0.33) CTSK
SCHEMBL10107622 0.77 CTSK (0.31) HPGDMEN1RAB9AKMT2ACTSK
SCHEMBL10516000 0.77 SQOR (0.35) CYP3A4KCNH2CYP1A2ALDH1A1HPGD
SCHEMBL10107582 0.75 KCNN4 (0.36)
SCHEMBL10400260 0.74 PTPN1 (0.42) CASRPTPN1CYP3A4CYP2D6SLC6A2
SCHEMBL14339779 0.72 CYP2A6 (0.40) CASRPTPN1CYP3A4CYP2D6SLC6A2
SCHEMBL6724607 0.72 CA1 (0.37) CYP3A4CYP1A2CYP2A6CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677461-B2 CYANOSILATION CATALYST JAPAN AS REPRESENTED BY PRESIDENT OF THE UNIVERSITY OF TOKYO (JP) 2004-01-13 US disclosed
US-20030119659-A1 Ligands and asymmetric catalysts made by using the same JAPAN AS REPRESENTED BY PRESIDENT OF THE UNIVERSITY OF TOKYO (JP) 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119659-A1 Ligands and asymmetric catalysts made by using the same AP2A1, AP3D1, AP3M1 CASR 3207/4885PTPN1 341/4885CYP3A4 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.